证券代码：600129 证券简称：太极集团 公告编号：2025-042 重庆太极实业（集团）股份有限公司 关于公司控股股东股权解押及质押的公告 | 行 | | | | | 转提 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 | | | | | | | | | | | | | | | 供担 | | | | | | | | | | | | | | | 保 | | | | | | | | | | | | | | | 合计 | | 534 | | | | | | | | | 3.47% | | 0.96% | | | | 或其他保障用途。 | | | | | | | | | | | | | | | | | | | 截至公告披露日，上述股东及其一致行动人累计质押股份情况如 | | | | | | | | | | 下: | | | | | | | | | | | | | | | | | | | | | | | | 已质押股份 | | | 未质 | | ...

证券代码：600129 证券简称：太极集团 公告编号：2025-042 重庆太极实业（集团）股份有限公司 关于公司控股股东股权解押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示: 重庆太极实业（集团）股份有限公司（以下简称：公司）控股股 东太极集团有限公司(以下简称：太极有限)持有公司股份 15,381.24 万股，占公司总股本的 27.62%。本次解除质押及再次质押后,太极有 限及其一致行动人累计质押股份 3,634.00 万股，占其所持股份的 23.63%，占公司总股本的 6.53%。 2 股东名称 太极集团有限公司 本次解质股份 800万股 占其所持股份比例 5.2% 占公司总股本比例 1.44% 解质时间 2025年6月9日 持股数量 15,381.24万股 持股比例 27.62% 剩余被质押股份数量 3,100万股 剩余被质押股份数量占其所持股份比例 20.15% 剩余被质押股份数量占公司总股本比例 5.57% 一、本次股份质押解除情况 二、本次股份质押基本情况 2、本次质押股份未被用作 ...

重庆太极实业（集团）股份有限公司（以下简称：公司）董事会 于近日收到副总经理谭礼文先生的书面辞职报告。谭礼文先生因达法 定退休年龄，申请辞去公司副总经理职务。 证券代码：600129 证券简称：太极集团 公告编号：2025-041 重庆太极实业（集团）股份有限公司 关于公司高级管理人员退休离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 2025 年 6 月 11 日 1 二、离任对公司的影响 姓名 离任 职务 离任时间 原定任期到期日 离任 原因 是否继续在 上市公司及 其控股子公 司任职 具体 职务 （如 适用） 是否存在 未履行完 毕的公开 承诺 谭礼文 副总 经理 2025 年 6 月 9 日 2024 年 5 月 18 日 退休 否 / 否 一、高级管理人员离任情况 特此公告。 重庆太极实业（集团）股份有限公司 根据《公司法》《公司章程》等相关规定，谭礼文先生的辞职报 告自送达公司董事会之日起生效。谭礼文先生已按照公司相关规定完 成了工作交接，其辞职不会影响公司日常经营的正常运行。 公司董事会对谭礼文先生 ...

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting, where key proposals including financial reports and board reports will be discussed and voted on by shareholders [1][2][3] Group 1: Meeting Arrangements - The meeting will take place on June 17, 2025, at the Huabin International Hotel in Beijing, with both on-site and online voting options for shareholders [1] - Shareholders can choose either on-site or online voting, but not both, to ensure the integrity of the voting process [1] Group 2: Board and Supervisory Reports - The company has prepared its 2024 Board Report and Supervisory Report in compliance with the requirements of the Hong Kong Stock Exchange and Shanghai Stock Exchange, which will be presented for shareholder approval [1][2] - The Supervisory Board has conducted thorough oversight of the company's operations and financial reporting, ensuring compliance with relevant laws and regulations [2][3] Group 3: Financial Performance and Profit Distribution - The company reported a net profit of 5,669.855 million RMB for 2024, with a proposed dividend distribution of 0.21 RMB per share, totaling 2,147.788 million RMB [9][10] - The proposed dividend distribution represents 45.72% of the distributable net profit attributable to shareholders [9] Group 4: Related Party Transactions - Significant related party transactions include agreements with China Huadian Group, involving a total estimated amount of 811 million RMB for various services and financial arrangements [3][4][5] - The company has renewed financial service agreements with its financial subsidiary, setting a maximum annual credit limit of 45 billion RMB [4][5] Group 5: Independent Directors' Reports - The independent directors have actively participated in governance, ensuring compliance with laws and protecting the interests of minority shareholders [12][14] - They have reviewed and approved various proposals, including the appointment of directors and financial management plans, maintaining a focus on transparency and accountability [12][14][21]

Core Viewpoint - The blood product giant, Palin Biotech, is set to be acquired by China National Pharmaceutical Group (Sinopharm), marking another change in ownership within two years [1][2]. Group 1: Ownership Change - On June 9, Palin Biotech announced that its controlling shareholder, Shengbang Yinghao Investment Partnership, plans to transfer 21.03% of its shares to China National Biotechnology Co., Ltd [1]. - If the transaction proceeds, the controlling shareholder will shift from Shengbang Yinghao to China National Biotechnology, with the actual controller changing from the Shaanxi Provincial State-owned Assets Supervision and Administration Commission to Sinopharm [1]. - This marks the second ownership change for Palin Biotech in less than two years, following a previous transfer of 20.99% of shares to Shengbang Yinghao in March 2023 [2]. Group 2: Financial Performance - In 2024, Palin Biotech reported a revenue of 2.655 billion yuan, a year-on-year increase of 14%, and a net profit of 745 million yuan, up 21.76%, marking seven consecutive years of profit growth [3]. - However, in Q1 2025, the company experienced a revenue decline of 14% to 375 million yuan and a net profit decrease of 26.95% to approximately 89.09 million yuan [3]. - The decline in Q1 2025 is attributed to insufficient production capacity to meet growing demand, prompting expansion efforts at its subsidiaries [3]. Group 3: Capacity Expansion - Palin Biotech is currently expanding production capacity at its subsidiaries, with the second phase of expansion at Paisfiko expected to be completed before the 2025 Spring Festival [3]. - The second phase expansion at Guangdong Shuanglin is anticipated to commence production in mid-2025, increasing annual capacity to 1,500 tons, contributing to a total capacity exceeding 3,000 tons [3]. - This expansion aims to support the company's growth and ensure sustainable long-term development [3]. Group 4: Regulatory Compliance - In May 2023, Palin Biotech faced penalties due to internal control issues leading to inaccurate information disclosure [3]. - The company submitted a rectification report on June 3, 2023, committing to enhance internal compliance management and improve information disclosure practices [4].

1 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 6 月 11 日 重庆太极实业（集团）股份有限公司 关于公司高级管理人员退休离任的公告 二、离任对公司的影响 证券代码：600129 证券简称：太极集团 公告编号：2025-041 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 根据《公司法》《公司章程》等相关规定，谭礼文先生的辞职报 告自送达公司董事会之日起生效。谭礼文先生已按照公司相关规定完 成了工作交接，其辞职不会影响公司日常经营的正常运行。 重庆太极实业（集团）股份有限公司（以下简称：公司）董事会 于近日收到副总经理谭礼文先生的书面辞职报告。谭礼文先生因达法 定退休年龄，申请辞去公司副总经理职务。 公司董事会对谭礼文先生在任职期间为公司发展所作出的贡献 表示衷心的感谢。 姓名 离任 职务 离任时间 原定任期到期日 离任 原因 是否继续在 上市公司及 其控股子公 司任职 具体 职务 （如 适用） 是否存在 未履行完 毕的公开 承诺 谭礼文 副总 经理 2025 年 6 月 9 日 2024 年 5 月 1 ...

Group 1 - The consumer sector is experiencing strong gains, with the Consumer 80 Index rising over 0.8% [1] - Several stocks, including Baili Tianheng and Ailis, have seen significant increases, with Baili Tianheng up over 7% and Ailis up over 5% [1] - The recent 1 trillion yuan reverse repurchase operation by the central bank has improved liquidity and is expected to benefit sectors related to domestic demand [3] Group 2 - The central bank's liquidity injection is aimed at stimulating consumption and investment, aligning with the government's focus on prioritizing the recovery and expansion of consumption [3] - Sectors such as home appliances, automobiles, and services like tourism and dining are expected to benefit from favorable policies [3] - The Consumer ETF (SH510150) offers comprehensive coverage across various consumption sectors, including food, beverage, and healthcare, making it a strategic investment option [5] Group 3 - The pig farming sector has seen a decline in prices, with the average price dropping to 14.05 yuan per kilogram as of June 6, indicating a continued downward trend [7] - The reduction in pig prices and weights suggests a potential decrease in profitability for pig farming, leading to a slowdown in production capacity growth [9] - The livestock farming ETF (SH516670) includes a significant proportion of stocks related to pig farming, making it a relevant investment vehicle in the current market [5]

证券代码：600129 证券简称：太极集团 公告编号：2025-040 重庆太极实业（集团）股份有限公司 关于董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）董事会 于 2025 年 6 月 4 日收到董事赖波先生提交的书面辞职申请。因工作 变动原因，赖波先生申请辞去公司董事、董事会薪酬与考核委员会委 员职务。辞职后，赖波先生不再担任公司任何职务。 而未履行的承诺事项。 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 6 月 5 日 二、董事离任对公司的影响 2 赖波先生的辞职不会导致公司董事会人数低于法定最低人数，不 会影响公司董事会的正常运作和公司的日常生产经营。根据《公司法》 《公司章程》的相关规定，赖波先生的辞职申请自送达公司董事会之 日起生效。公司将根据相关规定，尽快完成董事的补选工作。 截至本公告披露日，赖波先生未持有公司股份，亦不存在应履行 1 姓名 离任职务 离任时间 原定任期 到期日 离任原因 是否继续在上 市公司及其控 股子公司 ...

Investment Rating - The report indicates a positive outlook for the gynecological menstrual regulation medications industry in China, driven by increasing female health awareness and supportive policies [3]. Core Insights - The gynecological menstrual regulation medications industry in China has shown steady growth, supported by rising demand and policy benefits, with a focus on women's health needs [3]. - The market is expected to expand further due to the emergence of the "she economy" and the aging population, highlighting the potential in menopause management and reproductive health segments [3]. - The industry is characterized by a dual approach of Western and traditional Chinese medicine, with Western medications primarily consisting of hormone-based drugs and Chinese medicine focusing on holistic treatment [4][5]. Summary by Sections Industry Overview - Menstrual disorders are common among women, with significant differences in treatment approaches between Western and Chinese medicine [4]. - The report defines gynecological menstrual regulation medications as those that adjust reproductive endocrine functions or overall physiological functions to restore normal menstrual cycles [35][36]. Market Size - The market for gynecological menstrual regulation medications is projected to reach 238.9 billion yuan in 2024, with a growth forecast to 312.8 billion yuan by 2029 [43]. - The growth is attributed to increased awareness of women's health and rising incidence of gynecological diseases, particularly among younger women [43][44]. Industry Chain Analysis - The upstream analysis indicates that rising raw material prices are increasing production costs, with leading companies showing resilience due to resource advantages [53][54]. - The midstream analysis reveals a stable growth in the market driven by consumer demand, with a concentration of market share among leading brands [57][61]. - The downstream analysis highlights the growth of online channels, providing significant development opportunities for the industry [65]. Competitive Landscape - The competitive landscape shows a mix of established companies and smaller players, with leading firms leveraging brand strength and distribution advantages [61][62]. - The report notes that traditional Chinese medicine products dominate the market, while Western medications are gaining traction due to their targeted treatment capabilities [43][44].

Investment Rating - The report indicates a positive outlook for the gynecological menstrual regulation medications industry in China, driven by increasing awareness of women's health and supportive policies [3]. Core Insights - The gynecological menstrual regulation medications industry in China has shown steady growth, propelled by rising market demand and policy benefits, with a focus on women's health needs [3]. - The market is expected to expand significantly due to the emergence of the "she economy" and the aging population, highlighting the potential in menopause management and reproductive health segments [3]. - The industry is characterized by a dual approach to treatment, with Western medicine focusing on hormonal therapies and traditional Chinese medicine emphasizing holistic care [4][5]. Summary by Sections Industry Overview - Menstrual disorders are common among women, with significant differences in treatment approaches between Western and Chinese medicine [4]. - The report defines gynecological menstrual regulation medications as drugs that restore normal menstrual cycles through endocrine regulation [35]. Market Size - The market for gynecological menstrual regulation medications is projected to reach 238.9 billion yuan in 2024, with a growth forecast to 312.8 billion yuan by 2029 [43]. - The market growth is attributed to increased demand for gynecological disease management and supportive policies, with a notable rise in awareness of women's health [41][43]. Industry Chain Analysis - The upstream analysis indicates that rising raw material prices are increasing production costs, impacting smaller companies more than larger ones [53][54]. - The midstream analysis shows a stable growth in the market driven by consumer demand, with a concentration of market share among leading companies [57][61]. - The downstream analysis highlights the growth of online sales channels, providing significant opportunities for the industry [65]. Competitive Landscape - The competitive landscape is marked by a mix of established brands and smaller players, with leading companies leveraging brand strength and distribution advantages [61][62]. - The report notes that traditional Chinese medicine products dominate the market, benefiting from their natural attributes and policy support [43][44].